跳转至内容
Merck

SML2494

Sigma-Aldrich

Pralatrexate

≥98% (HPLC)

别名:

(2S)-2-[[4-[(1RS)-1-[(2,4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid, 10-propargyl-10-deazaaminopterin, N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid, PDX

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H23N7O5
分子量:
477.47
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL

儲存溫度

−20°C

SMILES 字串

O=C([C@@H](NC(C1=CC=C(C(CC(N=C23)=CN=C3N=C(N=C2N)N)CC#C)C=C1)=O)CCC(O)=O)O

InChI

1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1

InChI 密鑰

OGSBUKJUDHAQEA-WMCAAGNKSA-N

生化/生理作用

Pralatrexate is an antifolate that selectively enters cancer cells expressing reduced folate carrier type 1 (RFC-1). Pralatrexate potently inhibits DHFR (dihydrofolate reductase).

象形圖

Health hazard

訊號詞

Warning

危險聲明

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jennifer E Amengual et al.
Blood, 131(4), 397-407 (2017-11-17)
Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractory PTCL, exhibiting response rates of 25% and
Enrica Marchi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(24), 6657-6661 (2013-08-24)
Folates are well known to be essential for many cellular processes, including cellular proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been shown to be potent therapeutic agents in many cancers. Over the past several decades
Owen A O'Connor et al.
Leukemia & lymphoma, 58(11), 2548-2557 (2017-07-26)
It has been nearly 8 years since pralatrexate became the first drug approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Like most drugs approved for a particular clinical indication

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门